Dan Feng is an Oncology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 22 publications with 670 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1470 Madison Ave
New York, NY 100296542
Telephone
212-241-6756Provider last certified this registry record 25 Sept 2023.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Eisai Inc.Program year20251 payment
- BioNTech SEProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55%Serotonin-3 Receptor Antagonist35%Ondansetron Odt100%Part D≥13 patientsPotassium supplement20%Potassium Chloride100%Part D<11 patientsCardiovascular
26.7%Loop diuretic26.7%Furosemide100%Part D<11 patientsNervous system
18.3%Phenothiazine18.3%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 788 Local type 2 stromal-myeloid signalling axis drives progression and immunotherapy resistance of colorectal cancer metastasis
Regular and Young Investigator Award Abstracts
2025 - Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Journal of Clinical Oncology
2025 - Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”